Please use this identifier to cite or link to this item: http://elar.urfu.ru/handle/10995/111816
Title: Problems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillation
Authors: Gusev, V. V.
Lvova, O. A.
Shamalov, N. A.
Issue Date: 2021
Publisher: Silicea-Poligraf
Silicea - Poligraf, LLC
Citation: Gusev V. V. Problems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillation / V. V. Gusev, O. A. Lvova, N. A. Shamalov. — DOI 10.1016/j.rinp.2021.104336 // Cardiovascular Therapy and Prevention (Russian Federation). — 2021. — Vol. 20. — Iss. 6. — P. 78-83. — 3044.
Abstract: The article describes the urgent problem of ischemic stroke prevention in patients with atrial fibrillation. It is proved that ischemic stroke in combination with AF is the most severe in terms of developing stable motor and speech disorders and disability. The frail older patients, as well as patients with swallowing disorders and reduced medical adherence present a special problem from this point of view. The most famous clinical studies on secondary prevention of cardioembolic stroke are RE-LY, ROCKET-AF, and ARISTOTLE. Based on subanalyses of randomized controlled trials, direct oral anticoagulants demonstrated a favorable efficacy profile in patients with atrial fibrillation and stroke/ transient ischemic attack, but the level of knowledge on each of them remained different. A number of advantages of rivaroxaban for primary and secondary prevention of stroke in patients with atrial fibrillation, including the elderly and patients with cognitive impairments and swallowing disorders, have been demonstrated. © 2021 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved.
Keywords: ATRIAL FIBRILLATION
DIRECT ORAL ANTICOAGULANTS
ISCHEMIC STROKE
SECONDARY PREVENTION
ANTICOAGULANT AGENT
RIVAROXABAN
ARTICLE
ATRIAL FIBRILLATION
CARDIOEMBOLIC STROKE
COGNITIVE DEFECT
DRUG EFFICACY
DYSPHAGIA
HUMAN
ISCHEMIC STROKE
MOTOR DYSFUNCTION
PROPHYLAXIS
RANDOMIZED CONTROLLED TRIAL (TOPIC)
SPEECH DISORDER
TRANSIENT ISCHEMIC ATTACK
URI: http://elar.urfu.ru/handle/10995/111816
Access: info:eu-repo/semantics/openAccess
RSCI ID: 46668097
SCOPUS ID: 85118292019
PURE ID: 23917728
ISSN: 1728-8800
DOI: 10.1016/j.rinp.2021.104336
metadata.dc.description.sponsorship: Relationships and Activities. This publication was supported by AO Bayer (PPM_RIVRU00581).
Appears in Collections:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Files in This Item:
File Description SizeFormat 
2-s2.0-85118292019.pdf175,57 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.